Hideaki Yokogawa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hideaki Yokogawa has a total of 51 co-authors. Here are the top co-authors by number of shared publications:
Kazuhisa Sugiyama
Department of Ophthalmology, Kanazawa University Hospital, Ishikawa, Japan
31 shared publicationsAkira Kobayashi
Department of Ophthalmology, Kanazawa University Hospital, Ishikawa-ken, Japan
20 shared publicationsNatsuko Mori
Department of Ophthalmology Kanazawa University Graduate School of Medical Science Kanazawa Japan
11 shared publications- Akira Kobayashi
Department of Ophthalmology, Kanazawa University Graduate School of Medical Science, 13-1 Takara-machi, Kanazawa-shi, Ishikawa-ken, 920-8641, Japan.
9 shared publications Natsuko Yamazaki
Department of Ophthalmology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
8 shared publications- Akira Kobayashi
Department of Ophthalmology, Kanazawa University Graduate School of Medical Science, Kanazawa, Japan
7 shared publications
Latest Publications
- Open Access
- 7 April 2026
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 42, 102578
Intrastromal misplacement of a foldable IOL during phacoemulsification: Intraoperative OCT identification of type-1 dua's layer separation
- 7 April 2026
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 42, 102578
Open AccessIntrastromal misplacement of a foldable IOL during phacoemulsification: Intraoperative OCT identification of type-1 dua's layer separation
- Open Access
- 1 October 2025
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 18, 1285-1289
Corneal Adverse Events Temporally Associated with Anti-TNF-α Therapy: Severe Fibrovascular Pannus and a Non-Pannus Epitheliopathy in Two Cases
Purpose: To describe two corneal adverse events temporally associated with anti–tumor necrosis factor-α (TNF-α) therapy—one with severe fibrovascular pannus and another with epithelial keratopathy without pannus. Methods: Two patients on anti-TNF-α agents underwent comprehensive ocular examinations. Management included modification or discontinuation of biologics as clinically indicated and intensified topical therapy. Results: Case 1 (pustular psoriasis on adalimumab) developed bilateral fibrovascular pannus with stromal changes. Ocular findings did not improve immediately after adalimumab discontinuation but gradually improved following macrolide, topical corticosteroid, and immunomodulatory therapy. Case 2 (Crohn’s disease on adalimumab then golimumab) presented with superior corneal haze and diffuse superficial punctate keratopathy without pannus and resolved with topical therapy alone. Conclusion: These cases raise the possibility that corneal adverse events—including severe pannus—may occur during anti-TNF-α therapy. Given the heterogeneity and potential confounders, causality cannot be established. Ophthalmic vigilance and further studies are warranted.
- 1 October 2025
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 18, 1285-1289
Open AccessCorneal Adverse Events Temporally Associated with Anti-TNF-α Therapy: Severe Fibrovascular Pannus and a Non-Pannus Epitheliopathy in Two Cases
Purpose: To describe two corneal adverse events temporally associated with anti–tumor necrosis factor-α (TNF-α) therapy—one with severe fibrovascular pannus and another with epithelial keratopathy without pannus. Methods: Two patients on anti-TNF-α agents underwent comprehensive ocular examinations. Management included modification or discontinuation of biologics as clinically indicated and intensified topical therapy. Results: Case 1 (pustular psoriasis on adalimumab) developed bilateral fibrovascular pannus with stromal changes. Ocular findings did not improve immediately after adalimumab discontinuation but gradually improved following macrolide, topical corticosteroid, and immunomodulatory therapy. Case 2 (Crohn’s disease on adalimumab then golimumab) presented with superior corneal haze and diffuse superficial punctate keratopathy without pannus and resolved with topical therapy alone. Conclusion: These cases raise the possibility that corneal adverse events—including severe pannus—may occur during anti-TNF-α therapy. Given the heterogeneity and potential confounders, causality cannot be established. Ophthalmic vigilance and further studies are warranted.
- 26 May 2025
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 69 (5) , 702-707
Descemet membrane endothelial keratoplasty after cataract surgery with presbyopia-correcting intraocular lens for coexisting Fuchs endothelial corneal dystrophy and cataract
Purpose To assess the outcomes of Descemet membrane endothelial keratoplasty (DMEK) staged after implantation of presbyopia-correcting intraocular lenses (IOLs) in patients with coexisting Fuchs endothelial corneal dystrophy (FECD) and cataract. Study design Retrospective, interventional case series Methods We enrolled six eyes of three patients with coexisting FECD and cataract (3 women, age 67.8 ± 6.5 years) treated with presbyopia-correcting IOL implantation, followed by DMEK. The modified Krachmer grade, visual outcomes, and incidence of intra- and postoperative complications were analyzed. Results Modified Krachmer FECD grades 4, 5, and 6 were observed in one, two, and three eyes, respectively. The mean best-corrected visual acuity (BCVA) was dissatisfactory with the primary presbyopia-correcting IOL (decimal 0.45), it improved significantly (decimal 1.0, P = 0.027) after DMEK and all eyes acquired satisfactory uncorrected distance and near (30 cm) vision (mean, decimal, distance 0.85 and near 0.56). The manifest spherical equivalent after DMEK was within the acceptable range (−0.375 D to 0.0 D). Rebubbling was required in four eyes, but no instances of other postoperative complications or primary graft failure were encountered. Conclusion DMEK staged after implantation of presbyopia-correcting IOLs is a viable option for patients with coexisting FECD and cataract.
- 26 May 2025
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 69 (5) , 702-707
Descemet membrane endothelial keratoplasty after cataract surgery with presbyopia-correcting intraocular lens for coexisting Fuchs endothelial corneal dystrophy and cataract
Purpose To assess the outcomes of Descemet membrane endothelial keratoplasty (DMEK) staged after implantation of presbyopia-correcting intraocular lenses (IOLs) in patients with coexisting Fuchs endothelial corneal dystrophy (FECD) and cataract. Study design Retrospective, interventional case series Methods We enrolled six eyes of three patients with coexisting FECD and cataract (3 women, age 67.8 ± 6.5 years) treated with presbyopia-correcting IOL implantation, followed by DMEK. The modified Krachmer grade, visual outcomes, and incidence of intra- and postoperative complications were analyzed. Results Modified Krachmer FECD grades 4, 5, and 6 were observed in one, two, and three eyes, respectively. The mean best-corrected visual acuity (BCVA) was dissatisfactory with the primary presbyopia-correcting IOL (decimal 0.45), it improved significantly (decimal 1.0, P = 0.027) after DMEK and all eyes acquired satisfactory uncorrected distance and near (30 cm) vision (mean, decimal, distance 0.85 and near 0.56). The manifest spherical equivalent after DMEK was within the acceptable range (−0.375 D to 0.0 D). Rebubbling was required in four eyes, but no instances of other postoperative complications or primary graft failure were encountered. Conclusion DMEK staged after implantation of presbyopia-correcting IOLs is a viable option for patients with coexisting FECD and cataract.
- Open Access
- 1 September 2024
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 17, 795-800
Busin Glide-Assisted Pull-Through Insertion of Artificial Corneal Endothelium (EndoArt)
Background: Currently, the push-in technique through the corneal tunnel using a blunt-tip spatula is used to insert an artificial corneal endothelium (EndoArt) into the anterior chamber (AC). The device is useful for patients with bullous keratopathy; however, it may be difficult to manipulate the very thin implant through hazy cornea. Unlike DMEK graft, it cannot be stained and the F-mark is faint. So, visualizing and orienting the implant is a real challenge especially through a hazy cornea and inadequate AC visualization. Therefore, alternative EndoArt implantation techniques are needed in patients with advanced endothelial dysfunction to avoid complications. Purpose: To report an alternative technique for EndoArt implantation using a Busin glide. Technique: The EndoArt was loaded onto the Busin glide with the concave side of the EndoArt facing upward and was then pulled/pushed into the Busin glide opening. After the Descemet’s membrane and endothelium were detached and removed in a circular fashion in a patient with advanced corneal endothelial decompensation, the Busin glide was inserted into the corneal incision, and the EndoArt was slowly pulled into the AC using retractor forceps. Finally, the air was injected into the AC. Conclusion: The Busin glide-assisted pull-through technique smoothly and securely inserted the EndoArt into the AC without upside-down attachment. This alternative technique can be useful for patients with a history of repeat intraocular surgeries or trauma with severe corneal edema to avoid potential complications such as epithelial implantation cysts or downgrowth.
- 1 September 2024
- Published by Taylor & Francis in International Medical Case Reports Journal
- Vol. ume 17, 795-800
Open AccessBusin Glide-Assisted Pull-Through Insertion of Artificial Corneal Endothelium (EndoArt)
Background: Currently, the push-in technique through the corneal tunnel using a blunt-tip spatula is used to insert an artificial corneal endothelium (EndoArt) into the anterior chamber (AC). The device is useful for patients with bullous keratopathy; however, it may be difficult to manipulate the very thin implant through hazy cornea. Unlike DMEK graft, it cannot be stained and the F-mark is faint. So, visualizing and orienting the implant is a real challenge especially through a hazy cornea and inadequate AC visualization. Therefore, alternative EndoArt implantation techniques are needed in patients with advanced endothelial dysfunction to avoid complications. Purpose: To report an alternative technique for EndoArt implantation using a Busin glide. Technique: The EndoArt was loaded onto the Busin glide with the concave side of the EndoArt facing upward and was then pulled/pushed into the Busin glide opening. After the Descemet’s membrane and endothelium were detached and removed in a circular fashion in a patient with advanced corneal endothelial decompensation, the Busin glide was inserted into the corneal incision, and the EndoArt was slowly pulled into the AC using retractor forceps. Finally, the air was injected into the AC. Conclusion: The Busin glide-assisted pull-through technique smoothly and securely inserted the EndoArt into the AC without upside-down attachment. This alternative technique can be useful for patients with a history of repeat intraocular surgeries or trauma with severe corneal edema to avoid potential complications such as epithelial implantation cysts or downgrowth.
- Open Access
- 19 August 2022
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 16, 2705-2711
Clinical Features of Glaucoma Associated with Cytomegalovirus Corneal Endotheliitis
Purpose: The purpose of this study was to highlight the manifestations of glaucoma associated with cytomegalovirus (CMV) corneal endotheliitis. Methods: We reviewed the 34 patients that met the diagnostic criteria for CMV endotheliitis in our hospital, with special attention to the glaucoma status, including onset of glaucoma, glaucoma in the fellow eye, visual field defects, intraocular pressure, and final outcomes. Results: Thirty-four eyes of 34 patients (mean age, 69.1 ± 13.1 years; 31 males [91.2%]) with CMV corneal endotheliitis were enrolled. Thirty-two eyes (94.1%) had a history of a glaucoma diagnosis, which had been treated for 10.0 ± 10.1 years. Glaucoma in the fellow eye was noted in 16 cases (47.1%) and a history of Posner-Schlossman syndrome was noted in 13 cases (38.2%). Visual fields measured using a Humphrey field analyzer were normal-to-early stage (MD>-6dB) in 16 eyes (47.1%) and middle-to-late stage (MD≤-6dB) in 18 eyes (52.9%). The intraocular pressure decreased from 22.4 ± 10.6 mmHg at the initial visit to 14.9 ± 7.9 mmHg after medical treatment, including 0.5% topical ganciclovir (GCV) with and without a systemic anti-CMV agent, corticosteroid eye drops, and an anti-glaucoma agent (p< 0.01). During the follow-up period of 4.8 ± 3.0 years (range, 0.2– 10 years), 16 eyes (47.1%) required glaucoma surgery, including filtering surgery (7 eyes) and trabeculotomy only (9 eyes). Conclusion: Our case series showed that most of the patients with CMV corneal endotheliitis had glaucoma. Although medical therapy, including 0.5% topical GCV, had efficacy in lowering the intraocular pressure, one-half of the cases required glaucoma surgery. Therefore, ophthalmologists should strive to make an earlier diagnosis of CMV corneal endotheliitis by utilizing PCR testing of aqueous humor samples to prevent sight-threatening glaucomatous damage.
- 19 August 2022
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 16, 2705-2711
Open AccessClinical Features of Glaucoma Associated with Cytomegalovirus Corneal Endotheliitis
Purpose: The purpose of this study was to highlight the manifestations of glaucoma associated with cytomegalovirus (CMV) corneal endotheliitis. Methods: We reviewed the 34 patients that met the diagnostic criteria for CMV endotheliitis in our hospital, with special attention to the glaucoma status, including onset of glaucoma, glaucoma in the fellow eye, visual field defects, intraocular pressure, and final outcomes. Results: Thirty-four eyes of 34 patients (mean age, 69.1 ± 13.1 years; 31 males [91.2%]) with CMV corneal endotheliitis were enrolled. Thirty-two eyes (94.1%) had a history of a glaucoma diagnosis, which had been treated for 10.0 ± 10.1 years. Glaucoma in the fellow eye was noted in 16 cases (47.1%) and a history of Posner-Schlossman syndrome was noted in 13 cases (38.2%). Visual fields measured using a Humphrey field analyzer were normal-to-early stage (MD>-6dB) in 16 eyes (47.1%) and middle-to-late stage (MD≤-6dB) in 18 eyes (52.9%). The intraocular pressure decreased from 22.4 ± 10.6 mmHg at the initial visit to 14.9 ± 7.9 mmHg after medical treatment, including 0.5% topical ganciclovir (GCV) with and without a systemic anti-CMV agent, corticosteroid eye drops, and an anti-glaucoma agent (p< 0.01). During the follow-up period of 4.8 ± 3.0 years (range, 0.2– 10 years), 16 eyes (47.1%) required glaucoma surgery, including filtering surgery (7 eyes) and trabeculotomy only (9 eyes). Conclusion: Our case series showed that most of the patients with CMV corneal endotheliitis had glaucoma. Although medical therapy, including 0.5% topical GCV, had efficacy in lowering the intraocular pressure, one-half of the cases required glaucoma surgery. Therefore, ophthalmologists should strive to make an earlier diagnosis of CMV corneal endotheliitis by utilizing PCR testing of aqueous humor samples to prevent sight-threatening glaucomatous damage.
- Open Access
- 10 February 2022
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 25, 101414
Intraoperative optical coherence tomography-guided nanothin Descemet stripping automated endothelial keratoplasty in a patient with a remarkably thickened cornea
- 10 February 2022
- Published by Elsevier in American Journal of Ophthalmology Case Reports
- Vol. 25, 101414
Open AccessIntraoperative optical coherence tomography-guided nanothin Descemet stripping automated endothelial keratoplasty in a patient with a remarkably thickened cornea
- 16 March 2021
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 65 (4) , 454-459
Long-term outcomes of Descemet stripping automated endothelial keratoplasty for bullous keratopathy after argon laser iridotomy
Purpose To report the long-term outcomes of Descemet stripping automated endothelial keratoplasty (DSAEK) for bullous keratopathy secondary to argon laser iridotomy (BK-ALI). Study design Retrospective chart review. Methods Forty-five eyes from 41 consecutive patients with BK-ALI who underwent DSAEK from July 2007 to December 2013 were retrospectively analyzed. Best spectacle-corrected visual acuity (BCVA), endothelial cell density (ECD), and any complications were investigated over a 10-year postoperative period. Results The mean BCVA improved from 0.80 logMAR before DSAEK to 0.28 logMAR at 6 months after DSAEK; the mean values showed an additional slight improvement between 6 months and 10 years after the surgery (P < .01). The mean ECD decreased from 2864 cells/mm2 at baseline to 2269 cells/mm2 (20.8% loss) at 6 months post-DSAEK, and this decreasing trend continued throughout the 10 years after DSAEK (P < .01). The mean ECD was 1148 cells/mm2 (59.9% loss) after 5 years, and 568 cells/mm2 (80.2% loss) after 10 years. No graft deaths were observed throughout the 10-year period (5-year follow-up rate 60.0%, 10-year follow-up rate 20.0%). Conclusions The 10-year outcomes of DSAEK for BK-ALI were excellent with a high graft survival rate.
- 16 March 2021
- Published by Springer Nature in Japanese Journal of Ophthalmology
- Vol. 65 (4) , 454-459
Long-term outcomes of Descemet stripping automated endothelial keratoplasty for bullous keratopathy after argon laser iridotomy
Purpose To report the long-term outcomes of Descemet stripping automated endothelial keratoplasty (DSAEK) for bullous keratopathy secondary to argon laser iridotomy (BK-ALI). Study design Retrospective chart review. Methods Forty-five eyes from 41 consecutive patients with BK-ALI who underwent DSAEK from July 2007 to December 2013 were retrospectively analyzed. Best spectacle-corrected visual acuity (BCVA), endothelial cell density (ECD), and any complications were investigated over a 10-year postoperative period. Results The mean BCVA improved from 0.80 logMAR before DSAEK to 0.28 logMAR at 6 months after DSAEK; the mean values showed an additional slight improvement between 6 months and 10 years after the surgery (P < .01). The mean ECD decreased from 2864 cells/mm2 at baseline to 2269 cells/mm2 (20.8% loss) at 6 months post-DSAEK, and this decreasing trend continued throughout the 10 years after DSAEK (P < .01). The mean ECD was 1148 cells/mm2 (59.9% loss) after 5 years, and 568 cells/mm2 (80.2% loss) after 10 years. No graft deaths were observed throughout the 10-year period (5-year follow-up rate 60.0%, 10-year follow-up rate 20.0%). Conclusions The 10-year outcomes of DSAEK for BK-ALI were excellent with a high graft survival rate.
- 25 January 2021
- Published by Wolters Kluwer Health in Cornea
- Vol. 40 (11) , 1491-1497
Development of Cytomegalovirus Corneal Endotheliitis During Long-Term Topical Tacrolimus and Steroid Treatment for Chronic Ocular Surface Inflammatory Diseases
Purpose: We report 3 cases of patients with chronic ocular surface inflammatory disease who developed cytomegalovirus (CMV) corneal endotheliitis during immunosuppressant and steroid treatment. Patients and Methods: This is a retrospective observational study analyzing the clinical characteristics and outcomes of 3 patients with ocular surface inflammatory diseases (2 with Mooren ulcer and 1 with idiopathic scleritis) who developed CMV corneal endotheliitis. All patients developed CMV corneal endotheliitis between 8 and 14 months of starting steroid and immunosuppressant treatment, including topical 0.1% tacrolimus. Decimal visual acuity, endothelial counts, and intraocular pressure were analyzed. Results: All patients received topical 0.5% ganciclovir after the diagnosis of CMV corneal endotheliitis, which improved endothelial inflammation. However, all patients developed irreversible mydriasis and required additional surgeries, including endothelial keratoplasty, cataract surgery, and glaucoma surgery. At the final follow-up (14–46 months post-CMV corneal endotheliitis onset), fair outcomes were achieved, as demonstrated by a mean decimal best-corrected visual acuity of 0.3 and a well-controlled intraocular pressure. Conclusions: Topical steroids and immunosuppressants can induce fulminant CMV corneal endotheliitis with cataract progression and irreversible mydriasis. In these cases, early diagnosis and treatment, including topical 0.5% ganciclovir, glaucoma surgery, cataract surgery, and endothelial keratoplasty, are necessary for preserving the patient's vision.
- 25 January 2021
- Published by Wolters Kluwer Health in Cornea
- Vol. 40 (11) , 1491-1497
Development of Cytomegalovirus Corneal Endotheliitis During Long-Term Topical Tacrolimus and Steroid Treatment for Chronic Ocular Surface Inflammatory Diseases
Purpose: We report 3 cases of patients with chronic ocular surface inflammatory disease who developed cytomegalovirus (CMV) corneal endotheliitis during immunosuppressant and steroid treatment. Patients and Methods: This is a retrospective observational study analyzing the clinical characteristics and outcomes of 3 patients with ocular surface inflammatory diseases (2 with Mooren ulcer and 1 with idiopathic scleritis) who developed CMV corneal endotheliitis. All patients developed CMV corneal endotheliitis between 8 and 14 months of starting steroid and immunosuppressant treatment, including topical 0.1% tacrolimus. Decimal visual acuity, endothelial counts, and intraocular pressure were analyzed. Results: All patients received topical 0.5% ganciclovir after the diagnosis of CMV corneal endotheliitis, which improved endothelial inflammation. However, all patients developed irreversible mydriasis and required additional surgeries, including endothelial keratoplasty, cataract surgery, and glaucoma surgery. At the final follow-up (14–46 months post-CMV corneal endotheliitis onset), fair outcomes were achieved, as demonstrated by a mean decimal best-corrected visual acuity of 0.3 and a well-controlled intraocular pressure. Conclusions: Topical steroids and immunosuppressants can induce fulminant CMV corneal endotheliitis with cataract progression and irreversible mydriasis. In these cases, early diagnosis and treatment, including topical 0.5% ganciclovir, glaucoma surgery, cataract surgery, and endothelial keratoplasty, are necessary for preserving the patient's vision.
- Open Access
- 1 January 2020
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 14, 2119-2123
Visibility of the Retina Through an Air-Filled Anterior Chamber During Simultaneous Vitrectomy and Descemet's Stripping Automated Endothelial Keratoplasty
Purpose: To describe the visibility of the retina through an air-filled anterior chamber during simultaneous pars plana vitrectomy (PPV) and Descemet's stripping automated endothelial keratoplasty (DSAEK), and to discuss the technical challenges of a fluid-air exchange under such conditions. Methods: Six eyes from 6 patients with coexisting bullous keratopathy and posterior segment problems such as vitreous opacity, retained silicon oil, intraocular lens subluxation, or aphakia underwent simultaneous PPV and DSAEK. In all cases, after completion of 25-gauge PPV with/without flanged intrascleral intraocular lens fixation, DSAEK donor tissue was inserted into the anterior chamber. Air was then injected into the anterior chamber to attach the donor graft to the back surface of the host cornea. At this point, the visibility of the retina was evaluated using endoillumination and a wide-angle viewing system. Results: In all cases, visibility of the retina through an air-filled anterior chamber, with the DSAEK donor attached, was sufficient to perform a fluid-air exchange. Conclusion: Our clinical observations of such rare but clinically important conditions indicate that simultaneous PPV and DSAEK is possible with fair visualization of the posterior segment including the retina.
- 1 January 2020
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. 14, 2119-2123
Open AccessVisibility of the Retina Through an Air-Filled Anterior Chamber During Simultaneous Vitrectomy and Descemet's Stripping Automated Endothelial Keratoplasty
Purpose: To describe the visibility of the retina through an air-filled anterior chamber during simultaneous pars plana vitrectomy (PPV) and Descemet's stripping automated endothelial keratoplasty (DSAEK), and to discuss the technical challenges of a fluid-air exchange under such conditions. Methods: Six eyes from 6 patients with coexisting bullous keratopathy and posterior segment problems such as vitreous opacity, retained silicon oil, intraocular lens subluxation, or aphakia underwent simultaneous PPV and DSAEK. In all cases, after completion of 25-gauge PPV with/without flanged intrascleral intraocular lens fixation, DSAEK donor tissue was inserted into the anterior chamber. Air was then injected into the anterior chamber to attach the donor graft to the back surface of the host cornea. At this point, the visibility of the retina was evaluated using endoillumination and a wide-angle viewing system. Results: In all cases, visibility of the retina through an air-filled anterior chamber, with the DSAEK donor attached, was sufficient to perform a fluid-air exchange. Conclusion: Our clinical observations of such rare but clinically important conditions indicate that simultaneous PPV and DSAEK is possible with fair visualization of the posterior segment including the retina.
- 7 December 2019
- Published by Wolters Kluwer Health in Cornea
- Vol. 39 (4) , 523-526
Clinical Evaluation of the “Lifeline Suture” Technique for DSAEK in Cases Without Posterior Capsule Using a Novel Donor Insertion Device
This study investigated preliminary clinical outcomes of a suture pull-through technique for Descemet stripping automated endothelial keratoplasty (DSAEK) termed the “lifeline suture” technique using a newly developed donor inserter (NS Endo-Inserter: NSI; Hoya Co, Ltd, Tokyo, Japan) in cases of bullous keratopathy without posterior capsule. Six aphakic eyes without posterior capsule from 6 patients (mean age 73.8 ± 11.9 years) with bullous keratopathy were enrolled. DSAEK alone or as a vitreocorneal surgery was performed. Donor tissue was pulled into the anterior chamber using the NSI and a 9-0 polypropylene “lifeline suture” to prevent donor tissue from slipping into the vitreous cavity, which was removed at the end of surgery. Intraoperative and postoperative complications and 6-month postoperative central donor endothelial cell densities were measured and compared with preoperative values along with 6-month best-corrected visual acuity. All donors were successfully loaded into the NSI and then pulled into the anterior chamber using the lifeline suture. No intraoperative complications, graft dislocation, or primary graft failures were noted. Six months postsurgery, mean endothelial cell density was 2027 ± 747 cells/mm2 (mean loss 27.2 ± 28.1%) and mean best-corrected visual acuity improved to 0.31 decimal (P = 0.018). In this preliminary case series of bullous keratopathy without posterior capsule, DSAEK outcomes using the novel NSI donor inserter with lifeline suture were comparable or better than the results expected with conventional strategies. Thus, this technique enabled apparently safe DSAEK, preventing donor migration into the vitreous cavity while maintaining a stable anterior chamber, and is suitable for complex eyes including aphakia, lacking posterior capsule, or avitreal.
- 7 December 2019
- Published by Wolters Kluwer Health in Cornea
- Vol. 39 (4) , 523-526
Clinical Evaluation of the “Lifeline Suture” Technique for DSAEK in Cases Without Posterior Capsule Using a Novel Donor Insertion Device
This study investigated preliminary clinical outcomes of a suture pull-through technique for Descemet stripping automated endothelial keratoplasty (DSAEK) termed the “lifeline suture” technique using a newly developed donor inserter (NS Endo-Inserter: NSI; Hoya Co, Ltd, Tokyo, Japan) in cases of bullous keratopathy without posterior capsule. Six aphakic eyes without posterior capsule from 6 patients (mean age 73.8 ± 11.9 years) with bullous keratopathy were enrolled. DSAEK alone or as a vitreocorneal surgery was performed. Donor tissue was pulled into the anterior chamber using the NSI and a 9-0 polypropylene “lifeline suture” to prevent donor tissue from slipping into the vitreous cavity, which was removed at the end of surgery. Intraoperative and postoperative complications and 6-month postoperative central donor endothelial cell densities were measured and compared with preoperative values along with 6-month best-corrected visual acuity. All donors were successfully loaded into the NSI and then pulled into the anterior chamber using the lifeline suture. No intraoperative complications, graft dislocation, or primary graft failures were noted. Six months postsurgery, mean endothelial cell density was 2027 ± 747 cells/mm2 (mean loss 27.2 ± 28.1%) and mean best-corrected visual acuity improved to 0.31 decimal (P = 0.018). In this preliminary case series of bullous keratopathy without posterior capsule, DSAEK outcomes using the novel NSI donor inserter with lifeline suture were comparable or better than the results expected with conventional strategies. Thus, this technique enabled apparently safe DSAEK, preventing donor migration into the vitreous cavity while maintaining a stable anterior chamber, and is suitable for complex eyes including aphakia, lacking posterior capsule, or avitreal.